Ada Bertoli

Fonte dei dati: Archivio della Ricerca http://art.torvergata.it
  1. Alkhatib, M., Di Maio, V.C., De Murtas, V., Polilli, E., Milana, M., Teti, E., et al. (2021). Genetic Determinants in a Critical Domain of NS5A Correlate with Hepatocellular Carcinoma in Cirrhotic Patients Infected with HCV Genotype 1b. VIRUSES, 13(5), 743 [10.3390/v13050743]. Dettagli
  2. Piermatteo, L., Mohammad, A., Stefano, D., Vincenzo, M., Bertoli, A., Eleonora, A., et al. (2021). HBeAg Levels Vary across the Different Stages of HBV Infection According to the Extent of Immunological Pressure and Are Associated with Therapeutic Outcome in the Setting of Immunosuppression-Driven HBV Reactivation. BIOMEDICINES, 9(10), 1352 [10.3390/biomedicines9101352]. Dettagli
  3. Piermatteo, L., Scutari, R., Chirichiello, R., Alkhatib, M., Malagnino, V., Bertoli, A., et al. (2021). Droplet digital PCR assay as an innovative and promising highly sensitive assay to unveil residual and cryptic HBV replication in peripheral compartment. METHODS [10.1016/j.ymeth.2021.05.011]. Dettagli
  4. Salpini, R., Battisti, A., Piermatteo, L., Carioti, L., Anastasiou, O.E., Gill, U.S., et al. (2020). Key mutations in the C-terminus of the HBV surface glycoprotein correlate with lower HBsAg levels in vivo, hinder HBsAg secretion in vitro and reduce HBsAg structural stability in the setting of HBeAg-negative chronic HBV genotype-D infection. EMERGING MICROBES & INFECTIONS, 9(1), 928-939 [10.1080/22221751.2020.1757998]. Dettagli
  5. Scutari, R., Piermatteo, L., Ciancio Manuelli, M., Iannetta, M., Salpini, R., Bertoli, A., et al. (2020). Long-Term SARS-CoV-2 Infection Associated with Viral Dissemination in Different Body Fluids Including Bile in Two Patients with Acute Cholecystitis. LIFE, 10(11), 1-9. Dettagli
  6. Scutari, R., Piermatteo, L., Ciancio Manuelli, M., Iannetta, M., Salpini, R., Bertoli, A., et al. (2020). Long-term SARS-CoV-2 infection associated with viral dissemination in different body fluids Including bile in two patients with acute cholecystitis. LIFE, 10(11) [10.3390/life10110302]. Dettagli
  7. Salpini, R., Piermatteo, L., Battisti, A., Colagrossi, L., Aragri, M., Yu La Rosa, K., et al. (2020). A Hyper-Glycosylation of HBV Surface Antigen Correlates with HBsAg-Negativity at Immunosuppression-Driven HBV Reactivation in Vivo and Hinders HBsAg Recognition in Vitro. VIRUSES, 12(2), 251 [10.3390/v12020251]. Dettagli
  8. Armenia, D., Di Carlo, D., Flandre, P., Bouba, Y., Borghi, V., Forbici, F., et al. (2020). HIV MDR is still a relevant issue despite its dramatic drop over the years. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 75(5), 1301-1310 [10.1093/jac/dkz554]. Dettagli
  9. Salpini, R., Malagnino, V., Piermatteo, L., Mulas, T., Alkhatib, M., Scutari, R., et al. (2020). Cryptic HBV replicative activity is frequently revealed in anti-HBC-positive/hbsag-negative patients with HIV infection by highly sensitive molecular assays, and can be predicted by integrating classical and novel serological HBV markers. MICROORGANISMS, 8(11), 1-12. Dettagli
  10. Armenia, D., Di Carlo, D., Cozzi-Lepri, A., Calcagno, A., Borghi, V., Gori, C., et al. (2019). Very high pre-therapy viral load is a predictor of virological rebound in HIV-1-infected patients starting a modern first-line regimen. ANTIVIRAL THERAPY, 24(5), 321-331. Dettagli
  11. Bertoli, A., Sorbo, M.C., Aragri, M., Lenci, I., Teti, E., Polilli, E., et al. (2018). Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1-4 in Italy. SCIENTIFIC REPORTS, 8(1), 8988 [10.1038/s41598-018-26862-y]. Dettagli
  12. Di Maio, V.C., Cento, V., Aragri, M., Paolucci, S., Pollicino, T., Coppola, N., et al. (2018). Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens?. JOURNAL OF HEPATOLOGY, 68(3), 597-600. Dettagli
  13. Cento, V., Aragri, M., Teti, E., Polilli, E., Bertoli, A., Foroghi, L., et al. (2017). Optimal cure rate by personalized HCV regimens in real-life: a proof-of-concept study. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY [10.1093/jac/dkx302]. Dettagli
  14. Fabeni, L., Berno, G., Fokam, J., Bertoli, A., Alteri, C., Gori, C., et al. (2017). Comparative evaluation of subtyping tools for the surveillance of newly emerging HIV-1 strains. JOURNAL OF CLINICAL MICROBIOLOGY, JCM.00656-17 [10.1128/JCM.00656-17]. Dettagli
  15. Fabeni, L., Alteri, C., Di Carlo, D., Orchi, N., Carioti, L., Bertoli, A., et al. (2017). Dynamics and phylogenetic relationships of HIV-1 transmitted drug resistance according to subtype in Italy over the years 2000-14. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 72(10), 2837-2845 [10.1093/jac/dkx231]. Dettagli
  16. Soria, A., Alteri, C., Scarlatti, G., Bertoli, A., Tolazzi, M., Balestra, E., et al. (2017). Occupational HIV infection in a research laboratory with unknown mode of transmission: a case report. CLINICAL INFECTIOUS DISEASES, 64(6), 3-15 [10.1093/cid/ciw851]. Dettagli
  17. Armenia, D., Di Carlo, D., Calcagno, A., Vendemiati, G., Forbici, F., Bertoli, A., et al. (2016). Pre-existent NRTI and NNRTI resistance impacts on maintenance of virological suppression in HIV-1-infected patients who switch to a tenofovir/emtricitabine/rilpivirine single-tablet regimen. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, dkw512 [10.1093/jac/dkw512]. Dettagli
  18. Di Maio, V., Cento, V., Di Paolo, D., Aragri, M., De Leonardis, F., Tontodonati, M., et al. (2016). HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 71(3), 739-750 [10.1093/jac/dkv403]. Dettagli
  19. Maffongelli, G., Alterib, C., Gentilotti, E., Bertoli, A., Ricciardi, A., Malagnino, V., et al. (2016). Impact of HIV-1 tropism on the emergence of non-AIDS events in HIV-infected patients receiving fully suppressive antiretroviral therapy. AIDS [10.1097/QAD.0000000000000977]. Dettagli
  20. Palma, P., Zangari, P., Alteri, C., Tchidjou, H.k., Manno, E.c., Liuzzi, G., et al. (2016). Early antiretroviral treatment (eART) limits viral diversity over time in a long-term HIV viral suppressed perinatally infected child. BMC INFECTIOUS DISEASES, 16(1), 742 [10.1186/s12879-016-2092-z]. Dettagli
  21. Zaccarelli, M., Santoro, M.m., Armenia, D., Borghi, V., Gennari, W., Gori, C., et al. (2016). Genotypic resistance test in proviral DNA can identify resistance mutations never detected in historical genotypic test in patients with low level or undetectable HIV-RNA. JOURNAL OF CLINICAL VIROLOGY, 82, 94-100 [10.1016/j.jcv.2016.07.007]. Dettagli
  22. Surdo, M., Bertoli, A., Colucci, G., Sarmati, L., Andreoni, M., Perno, C.F., et al. (2015). Total HIV-1 DNA detection and quantification in peripheral blood by COBAS®AmpliPrep/COBAS® TaqMan® HIV-1 Test, v2.0. CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 54(2), e57-e59 [10.1515/cclm-2015-0647]. Dettagli
  23. Fabeni, L., Berno, G., Svicher, V., Ceccherini-Silberstein, F., Gori, C., Bertoli, A., et al. (2015). Genotypic tropism testing in HIV-1 proviral DNA can provide useful information at low-level viremia. JOURNAL OF CLINICAL MICROBIOLOGY, 53(9), 2935-2941 [10.1128/JCM.00893-15]. Dettagli
  24. Cento, V., Tontodonati, M., Di Maio, V.c., Bellocchi, M.c., Valenti, F., Manunta, A., et al. (2015). Kinetics of hepatitis C virus RNA decay, quasispecies evolution and risk of virological failure during telaprevir-based triple therapy in clinical practice. DIGESTIVE AND LIVER DISEASE, 47(3), 233-241 [10.1016/j.dld.2014.12.004]. Dettagli
  25. Fabeni, L., Alteri, C., Orchi, N., Gori, C., Bertoli, A., Forbici, F., et al. (2015). Recent transmission clustering of HIV-1 C and CRF17-BF strains characterized by NNRTI-related mutations among newly diagnosed men in central Italy. PLOS ONE, 10(8), e0135325 [10.1371/journal.pone.0135325]. Dettagli
  26. Mirabelli, C., Surdo, M., Van Hemert, F., Lian, Z., Salpini, R., Cento, V., et al. (2014). Specific mutations in the C-terminus domain of HBV surface antigen significantly correlate with low level of serum HBV-DNA in patients with chronic HBV infection. JOURNAL OF INFECTION [10.1016/j.jinf.2014.10.015]. Dettagli
  27. Armenia, D., Soulie, C., Di Carlo, D., Fabeni, L., Gori, C., Forbici, F., et al. (2014). A very low geno2pheno false positive rate is associated with poor viro-immunological response in drug-naïve patients starting a first-line HAART. PLOS ONE, 9(8) [10.1371/journal.pone.0105853]. Dettagli
  28. Santoro, M., Fabeni, L., Armenia, D., Alteri, C., Di Pinto, D., Forbici, F., et al. (2014). Reliability and clinical relevance of the HIV-1 drug resistance test in patients with low viremia levels. CLINICAL INFECTIOUS DISEASES, 58(8), 1156-1164 [10.1093/cid/ciu020]. Dettagli
  29. Svicher, V., Alteri, C., Montano, M., Nori, A., D'Arrigo, R., Andreoni, M., et al. (2014). Genotypic testing on HIV-1 DNA as a tool to assess HIV-1 co-receptor usage in clinical practice: results from the DIVA study group. INFECTION, 42(1), 61-71 [10.1007/s15010-013-0510-3]. Dettagli
  30. Cento, V., Van Hemert, F., Neumann Fraune, M., Mirabelli, C., Di Maio, V., Salpini, R., et al. (2013). Anti-HBV treatment induces novel reverse transcriptase mutations with reflective effect on HBV S antigen. JOURNAL OF INFECTION, 67(4), 303-312 [10.1016/j.jinf.2013.05.008]. Dettagli
  31. Alteri, C., Artese, A., Beheydt, G., Santoro, M., Costa, G., Parrotta, L., et al. (2013). Structural modifications induced by specific HIV-1 protease-compensatory mutations have an impact on the virological response to a first-line lopinavir/ritonavir-containing regimen. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 68(10), 2205-2209 [10.1093/jac/dkt173]. Dettagli
  32. Cento, V., Mirabelli, C., Dimonte, S., Salpini, R., Han, Y., Trimoulet, P., et al. (2012). Overlapping structure of HBV genome and immune selection pressure are critical forces modulating HBV evolution. JOURNAL OF GENERAL VIROLOGY [10.1099/vir.0.046524-0]. Dettagli
  33. Ciccozzi, M., Santoro, M., Giovanetti, M., Andrissi, L., Bertoli, A., & Ciotti, M. (2012). HIV-1 non-B subtypes in Italy: a growing trend. NEW MICROBIOLOGICA, 35(4), 377-386. Dettagli
  34. Santoro, M., Armenia, D., Fabeni, L., Santoro, M., Gori, C., Forbici, F., et al. (2012). The lowest X4 Geno2Pheno false-positive rate is associated with greater CD4 depletion in HIV-1 infected patients. CLINICAL MICROBIOLOGY AND INFECTION, 18(8) [10.1111/j.1469-0691.2012.03905.x]. Dettagli
  35. Svicher, V., Cento, V., Bernassola, M., Neumann-Fraune, M., Van Hemert, F., Chen, M., et al. (2012). Novel HBsAg markers tightly correlate with occult HBV infection and strongly affect HBsAg detection. ANTIVIRAL RESEARCH, 93(1), 86-93 [10.1016/j.antiviral.2011.10.022]. Dettagli
  36. Cento, V., Mirabelli, C., Salpini, R., Dimonte, S., Artese, A., Costa, G., et al. (2012). HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors. PLOS ONE, 7(7), e39652-e39652 [10.1371/journal.pone.0039652]. Dettagli
  37. Cento, V., Van Hemert, F., Di Maio, V., Salpini, R., Mirabelli, C., Bertoli, A., et al. (2012). Novel reverse transcriptase mutations specifically associated with selected anti-Hbv treatment can induce alterations and stop-codons in Hbv S antigen. In JOURNAL OF HEPATOLOGY (pp.S198-S199). Dettagli
  38. Santoro, M.M., Alteri, C., Ronga, L., Flandre, P., Fabeni, L., Mercurio, F., et al. (2012). Comparative Analysis of Drug Resistance Among B and the Most Prevalent Non-B HIV Type 1 Subtypes (C, F, and CRF02_AG) in Italy. AIDS RESEARCH AND HUMAN RETROVIRUSES, 28(10), 1285-1293 [10.1089/aid.2011.0142]. Dettagli
  39. Svicher, V., Alteri, C., Montano, M., D'Arrigo, R., Andreoni, M., Angarano, G., et al. (2012). Performance of genotypic tropism testing on proviral DNA in clinical practice: results from the DIVA Study Group. NEW MICROBIOLOGICA, 35(1), 17-25. Dettagli
  40. Svicher, V., Mirabelli, C., Cento, V., Salpini, R., Di Maio, V., Bertoli, A., et al. (2012). Key patterns of HBX and pre-S1/S2 mutations are involved in mechanisms underlying HBV-induced hepatocellular carcinoma in vivo. Paper presented at 47th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), Barcelona, SPAIN [10.1016/S0168-8278(12)60500-5]. Dettagli
  41. Alcaro, S., Alteri, C., Artese, A., Ceccherini-Silberstein, F., Costa, G., Ortuso, F., et al. (2011). Docking Analysis and Resistance Evaluation of Clinically Relevant Mutations Associated with the HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors Nevirapine, Efavirenz and Etravirine. CHEMMEDCHEM, 6(12), 2203-2213 [10.1002/cmdc.201100362]. Dettagli
  42. Ceccarelli, L., Salpini, R., Sarmati, L., Svicher, V., Bertoli, A., Sordillo, P., et al. (2011). Late hepatitis B virus reactivation after lamivudine prophylaxis interruption in an anti-HBs-positive and anti-HBc-negative patient treated with rituximab-containing therapy. JOURNAL OF INFECTION, 65(2) [10.1016/j.jinf.2011.11.021]. Dettagli
  43. Svicher, V., Cento, V., Bernassola, M., Neumann-Fraune, M., Hemert, F., Chen, M., et al. (2011). Novel HBsAg markers tightly correlate with occult HBV infection and strongly affect HBsAg detection. ANTIVIRAL RESEARCH, 93(1), 86-93 [10.1016/j.antiviral.2011.10.022]. Dettagli
  44. Sarrecchia, C., Svicher, V., Volpi, A., Salpini, R., Ceccarelli, L., Sordillo, P., et al. (2011). Successful switch to tenofovir after suboptimal response to entecavir in an immunocompromised patient with chronic hepatitis B and without genotypic hepatitis B virus resistance. INFECTION [10.1007/s15010-011-0127-3]. Dettagli
  45. Ciccozzi, M., Babakir-Mina, M., Cella, E., Bertoli, A., Lo Presti, A., Maniar, J., et al. (2011). A case of Italian HIV-2 infection: a genetic analysis. AIDS RESEARCH AND HUMAN RETROVIRUSES [10.1089/AID.2011.0055]. Dettagli
  46. Alteri, C., Artese, A., Zang, J.M., Mercurio, F., Costa, G., Stazi, F., et al. (2011). Signature mutations in V3 and bridging sheet domain of HIV-1 gp120 are specifically associated with dual tropism and modulate the interaction with CCR5 N-terminus. Paper presented at 3th ICAR – Italian Conference on AIDS and Retroviruses, Firenze, Italia. Dettagli
  47. Cento, V., Mirabelli, C., Salpini, R., Han, Y., Mercurio, F., Dimonte, S., et al. (2011). Overlapping Structure of HBV genome and immune selecting pressure are the main driving forces for HBV evolution. Paper presented at 46th Annual meeting of the European Association for the study of the liver, Berlin, Germany. Dettagli
  48. Salpini, R., Svicher, V., Cento, V., Gori, C., Bertoli, A., Scopelliti, F., et al. (2011). Characterization of drug-resistance mutations in HBV D-genotype chronically infected patients, naïve to antiviral drugs. ANTIVIRAL RESEARCH, 92(2), 382-385 [10.1016/j.antiviral.2011.08.013]. Dettagli
  49. Santoro, M., Armenia, D., Fabeni, L., Santoro, M., Gori, C., Forbici, F., et al. (2011). The Lowest X4 Geno2Pheno-False Positive Rate Is Associated with Greater CD4-Depletion. Paper presented at 3th ICAR – Italian Conference on AIDS and Retroviruses, Firenze, Italia. Dettagli
  50. Sarrecchia, C., Svicher, V., Volpi, A., Salpini, R., Ceccarelli, L., Sordillo, P., et al. (2011). Successful switch to tenofovir after suboptimal response to entecavir in an immunocompromised patient with chronic hepatitis B and without genotypic hepatitis B virus resistance. INFECTION [10.1007/s15010-011-0127-3.]. Dettagli
  51. Svicher, V., Cento, V., Bernassola, M., Neumann-Fraune, M., Chen, M., Salpini, R., et al. (2011). Specific HbsAg genetic determinants are associated with occult HBV infection in vivo and HbsAg detection. Paper presented at International Workshop on HIV & Hepatitis virus Drug Resistance and curative strategies, Los Cabos (Mexico). Dettagli
  52. Svicher, V., Cento, V., Salpini, R., Mercurio, F., Fraune, M., Beggel, B., et al. (2011). Role of hepatitis B virus genetic barrier in drug-resistance and immune-escape development. DIGESTIVE AND LIVER DISEASE, 43(12), 975-983 [10.1016/j.dld.2011.07.002]. Dettagli
  53. Svicher, V., Alteri, C., Gori, C., Salpini, R., Marcuccilli, F., Bertoli, A., et al. (2010). Lamivudine-resistance mutations can be selected even at very low levels of hepatitis B viraemia. DIGESTIVE AND LIVER DISEASE, 42(12), 902-907 [10.1016/j.dld.2010.04.017]. Dettagli
  54. Svicher, V., D'Arrigo, R., Alteri, C., Andreoni, M., Angarano, G., Antinori, A., et al. (2010). Performance of genotypic tropism testing in clinical practice using the enhanced sensitivity version of Trofile as reference assay: results from the OSCAR Study Group. NEW MICROBIOLOGICA, 33(3), 195-206. Dettagli
  55. Santoro, M., Bertoli, A., Lorenzini, P., Ceccherini-Silberstein, F., Gianotti, N., Mussini, C., et al. (2009). Two different patterns of mutations are involved in the genotypic resistance score for atazanavir boosted versus unboosted by ritonavir in multiple failing patients. INFECTION, 37(3), 233-243 [10.1007/s15010-008-8065-4]. Dettagli
  56. Tozzi, V., Bellagamba, R., Castiglione, F., Amendola, A., Ivanovic, J., Nicastri, E., et al. (2008). Plasma HIV RNA decline and emergence of drug resistance mutations among patients with multiple virologic failures receiving resistance testing-guided HAART. AIDS RESEARCH AND HUMAN RETROVIRUSES, 24(6), 787-796 [10.1089/aid.2007.0236]. Dettagli
  57. Santoro, M., Bertoli, A., Lorenzini, P., Lazzarin, A., Esposito, R., Carosi, G., et al. (2008). Viro-immunologic response to ritonavir-boosted or unboosted atazanavir in a large cohort of multiply treated patients: the CARe Study. AIDS PATIENT CARE AND STDS, 22(1), 7-16 [10.1089/apc.2007.0013]. Dettagli
  58. Ceccherini-Silberstein, F., Svicher, V., Sing, T., Artese, A., Santoro, M., Forbici, F., et al. (2007). Characterization and structural analysis of novel mutations in human immunodeficiency virus type 1 reverse transcriptase involved in the regulation of resistance to nonnucleoside inhibitors. JOURNAL OF VIROLOGY, 81(20), 11507-11519 [10.1128/JVI.00303-07]. Dettagli
  59. Zaccarelli, M., Tozzi, V., Lorenzini, P., Forbici, F., Narciso, P., Ceccherini-Silberstein, F., et al. (2007). The V118I mutation as a marker of advanced HIV infection and disease progression. ANTIVIRAL THERAPY, 12(2), 163-168. Dettagli
  60. Nadembega, W., Giannella, S., Simpore, J., Ceccherini-Silberstein, F., Pietra, V., Bertoli, A., et al. (2006). Characterization of drug-resistance mutations in HIV-1 isolates from non-HAART and HAART treated patients in Burkina Faso. JOURNAL OF MEDICAL VIROLOGY, 78(11), 1385-1391 [10.1002/jmv.20709]. Dettagli
  61. Aquaro, S., D'Arrigo, R., Svicher, V., Perri, G., Caputo, S., Visco-Comandini, U., et al. (2006). Specific mutations in HIV-1 gp41 are associated with immunological success in HIV-1-infected patients receiving enfuvirtide treatment. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 58(4), 714-722 [10.1093/jac/dkl306]. Dettagli
  62. Svicher, V., Sing, T., Santoro, M., Forbici, F., Rodríguez-Barrios, F., Bertoli, A., et al. (2006). Involvement of novel human immunodeficiency virus type 1 reverse transcriptase mutations in the regulation of resistance to nucleoside inhibitors. JOURNAL OF VIROLOGY, 80(14), 7186-7198 [10.1128/JVI.02084-05]. Dettagli
  63. Santoro, M., Svicher, V., Gori, C., Zaccarelli, M., Tozzi, V., Forbici, F., et al. (2006). Temporal characterization of drug resistance associated mutations in HIV-1 protease and reverse transcriptase in patients failing antiretroviral therapy. NEW MICROBIOLOGICA, 29(2), 89-100. Dettagli
  64. Tozzi, V., Zaccarelli, M., Bonfigli, S., Lorenzini, P., Liuzzi, G., Trotta, M., et al. (2006). Drug-class-wide resistance to antiretrovirals in HIV-infected patients failing therapy: prevalence, risk factors and virological outcome. ANTIVIRAL THERAPY, 11(5), 553-560. Dettagli
  65. Ceccherini-Silberstein, F., Gago, F., Santoro, M., Gori, C., Svicher, V., Rodríguez-Barrios, F., et al. (2005). High sequence conservation of human immunodeficiency virus type 1 reverse transcriptase under drug pressure despite the continuous appearance of mutations. JOURNAL OF VIROLOGY, 79(16), 10718-10729 [10.1128/JVI.79.16.10718-10729.2005]. Dettagli
  66. Bertoli, A., Franco, M., Balzarini, J., Johansson, M., & Karlsson, A. (2005). Altered deoxyribonucleotide pools in T-lymphoblastoid cells expressing the multisubstrate nucleoside kinase of Drosophila melanogaster. THE FEBS JOURNAL, 272(15), 3918-3928 [10.1111/j.1742-4658.2005.04808.x]. Dettagli
  67. Perno, C., Cozzi-Lepri, A., Forbici, F., Bertoli, A., Violin, M., Stella Mura, M., et al. (2004). Minor mutations in HIV protease at baseline and appearance of primary mutation 90M in patients for whom their first protease-inhibitor antiretroviral regimens failed. THE JOURNAL OF INFECTIOUS DISEASES, 189(11), 1983-1987 [10.1086/386307]. Dettagli
  68. Santoro, M., Ceccherini-Silberstein, F., Gori, C., Svicher, V., Forbici, F., Bellocchi, M., et al. (2004). Temporal change in the use of genotypic resistance testing over the years 1999--2003. NEW MICROBIOLOGICA, 27(2 Suppl 1), 141-144. Dettagli
  69. Violin, M., Cozzi-Lepri, A., Velleca, R., Vincenti, A., D'Elia, S., Chiodo, F., et al. (2004). Risk of failure in patients with 215 HIV-1 revertants starting their first thymidine analog-containing highly active antiretroviral therapy. AIDS, 18(2), 227-235 [10.1097/00002030-200401230-00012]. Dettagli
  70. Ceccherini-Silberstein, F., Erba, F., Gago, F., Bertoli, A., Forbici, F., Bellocchi, M., et al. (2004). Identification of the minimal conserved structure of HIV-1 protease in the presence and absence of drug pressure. AIDS, 18(12), 11-19 [10.1097/01.aids.0000131394.76221.02]. Dettagli
  71. MOLLACE, V., Salvemini, D., Riley, D., Muscoli, C., Iannone, M., Granato, T., et al. (2002). The contribution of oxidative stress in apoptosis of human-cultured astroglial cells induced by supernatants of HIV-1-infected macrophages. JOURNAL OF LEUKOCYTE BIOLOGY, 71(1), 65-72. Dettagli